Pub Date : 2024-12-01Epub Date: 2024-02-08DOI: 10.1080/09546634.2024.2312250
David M Weiner, Priyanka Kumar, Ravi Varadhan, Ronald Sweren, Noori Kim, Sima Rozati
{"title":"Outcomes of extracorporeal photopheresis in a diverse cohort of patients with cutaneous T-cell lymphoma: a retrospective study at a tertiary care hospital.","authors":"David M Weiner, Priyanka Kumar, Ravi Varadhan, Ronald Sweren, Noori Kim, Sima Rozati","doi":"10.1080/09546634.2024.2312250","DOIUrl":"10.1080/09546634.2024.2312250","url":null,"abstract":"","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139708919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01Epub Date: 2024-02-11DOI: 10.1080/09546634.2024.2311793
Gaurav N Pathak, Anurag N Pathak, Vibha Mital, Jimmy Dhillon, Steven R Feldman, Babar K Rao
{"title":"Vitiligo outpatient management in the United States: findings from the 2012-2019 National Ambulatory Medical care Survey (NAMCS).","authors":"Gaurav N Pathak, Anurag N Pathak, Vibha Mital, Jimmy Dhillon, Steven R Feldman, Babar K Rao","doi":"10.1080/09546634.2024.2311793","DOIUrl":"10.1080/09546634.2024.2311793","url":null,"abstract":"","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139718196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01Epub Date: 2024-01-23DOI: 10.1080/09546634.2024.2307495
M Cebolla-Verdugo, C Llamas-Segura, L Linares-González, R Ruiz-Villaverde, F J Navarro-Triviño
{"title":"A therapeutic challenge: managing severe atopic dermatitis with concurrent alpha-1-antitrypsin deficiency.","authors":"M Cebolla-Verdugo, C Llamas-Segura, L Linares-González, R Ruiz-Villaverde, F J Navarro-Triviño","doi":"10.1080/09546634.2024.2307495","DOIUrl":"10.1080/09546634.2024.2307495","url":null,"abstract":"","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139522039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01Epub Date: 2024-05-09DOI: 10.1080/09546634.2024.2351489
Giovanni Paolino, Alessandra Narcisi, Andrea Carugno, Piergiorgio Malagoli, Matteo R Di Nicola, Antonio Foti, Vittoria G Bianchi, Andrea Gustavo Locatelli, Paolo Sena, Antonio Costanzo, Santo R Mercuri, Mario Valenti
Background: Genital involvement in atopic dermatitis(AD) can have a significant impact on the patient's quality of life. However, inspection of genital areas is not usually conducted during routine examination and patients may be reluctant to inform the clinician or show this area.
Objective: to evaluate the efficacy of tralokinumab in AD patients with genital involvement.
Methods: Adult patients with moderate/severe AD and genital involvement receiving tralokinumab have been analyzed. Primary endpoints were EASI, DLQI, PP-NRS, genital-IGA (g-IGA) and genital itching (GI) at week 16.
Results: out of 48 patients with moderate/severe AD under treatment with tralokinumab, 12 patients (25%) showed a genital involvement. Seven patients reported itching in the genital area (58%), while none reported a positive history of genital infections. Median scores at T0 were EASI 17.5, PP-NRS 8 and DLQI 14. After 16 weeks of treatment, we observed a median EASI of 3, a median PP-NRS of 1 and a median DLQI of 1. Finally, concerning the genital response, after 16 weeks of treatment, we observed a statistically significant decrease in mean GI and g-IGA scores.
Conclusion: despite the small size of our sample, tralokinumab can be considered as a valid treatment option for AD with genital involvement.
{"title":"Successful use of tralokinumab for the treatment of atopic dermatitis on the genitals.","authors":"Giovanni Paolino, Alessandra Narcisi, Andrea Carugno, Piergiorgio Malagoli, Matteo R Di Nicola, Antonio Foti, Vittoria G Bianchi, Andrea Gustavo Locatelli, Paolo Sena, Antonio Costanzo, Santo R Mercuri, Mario Valenti","doi":"10.1080/09546634.2024.2351489","DOIUrl":"https://doi.org/10.1080/09546634.2024.2351489","url":null,"abstract":"<p><strong>Background: </strong>Genital involvement in atopic dermatitis(AD) can have a significant impact on the patient's quality of life. However, inspection of genital areas is not usually conducted during routine examination and patients may be reluctant to inform the clinician or show this area.</p><p><strong>Objective: </strong>to evaluate the efficacy of tralokinumab in AD patients with genital involvement.</p><p><strong>Methods: </strong>Adult patients with moderate/severe AD and genital involvement receiving tralokinumab have been analyzed. Primary endpoints were EASI, DLQI, PP-NRS, genital-IGA (g-IGA) and genital itching (GI) at week 16.</p><p><strong>Results: </strong>out of 48 patients with moderate/severe AD under treatment with tralokinumab, 12 patients (25%) showed a genital involvement. Seven patients reported itching in the genital area (58%), while none reported a positive history of genital infections. Median scores at T0 were EASI 17.5, PP-NRS 8 and DLQI 14. After 16 weeks of treatment, we observed a median EASI of 3, a median PP-NRS of 1 and a median DLQI of 1. Finally, concerning the genital response, after 16 weeks of treatment, we observed a statistically significant decrease in mean GI and g-IGA scores.</p><p><strong>Conclusion: </strong>despite the small size of our sample, tralokinumab can be considered as a valid treatment option for AD with genital involvement.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140900232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01Epub Date: 2024-05-08DOI: 10.1080/09546634.2024.2351493
Adaora R Ewulu, Rohan Singh, Kristina B Roberson, E J Masicampo, Steven R Feldman
{"title":"Toward a better understanding of treatment adherence: incorporating accountability explicitly into the social cognitive theory of adherence behavior.","authors":"Adaora R Ewulu, Rohan Singh, Kristina B Roberson, E J Masicampo, Steven R Feldman","doi":"10.1080/09546634.2024.2351493","DOIUrl":"https://doi.org/10.1080/09546634.2024.2351493","url":null,"abstract":"","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140893135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01Epub Date: 2024-05-20DOI: 10.1080/09546634.2024.2355261
Shan Huang, Xing-Wu Duan, Hua-Chao Zhang, Bo-Wen Dai, Yan-Ping Bai
Background: Biologics have revolutionized psoriasis treatment; however, relapse of psoriasis after discontinuation of biologics remains unresolved.
Objective: To assess the impact of adjunctive Chinese medicine (CM) therapy on relapse of psoriasis vulgaris (PV) after discontinuation of biologics.
Methods: We constructed a prospective cohort study through a psoriasis case registry platform that enrolled patients treated with biologics (in combination with or without CM). The endpoint event was relapse, defined as loss of psoriasis area and severity index (PASI) 75.
Results: A total of 391 patients completed the study and were included in the analysis, of whom 169 (43.2%) experienced relapse during follow-up. To minimize the bias, a 1:1 propensity score matching (PSM) was performed, generating matched cohorts of 156 individuals per group. Adjuvant CM therapy significantly associated with reduced incidence of relapse (HR =0.418, 95% CI = 0.289 ∼ 0.604, p < 0.001), and the protective effect of CM in the subgroup analysis was significant. In addition, PASI 90 response and disease duration were associated with relapse (p < 0.05).
Conclusion: Adjunctive CM therapy is associated with reduced relapse incidence in PV after discontinuation of biologics.
背景:生物制剂给银屑病治疗带来了革命性的变化,然而,停用生物制剂后银屑病复发的问题仍未得到解决:评估中医药辅助治疗对停用生物制剂后寻常型银屑病(PV)复发的影响:我们通过银屑病病例登记平台构建了一项前瞻性队列研究,纳入了接受生物制剂(联合或不联合中医药)治疗的患者。终点事件为复发,定义为银屑病面积和严重程度指数(PASI)下降至75:共有 391 名患者完成研究并纳入分析,其中 169 人(43.2%)在随访期间复发。为尽量减少偏差,研究人员进行了 1:1 的倾向得分匹配(PSM),每组产生了 156 人的匹配队列。CM辅助治疗与复发率的降低有明显相关性(HR =0.418, 95% CI = 0.289 ∼ 0.604, p p 结论:CM辅助治疗与复发率的降低有明显相关性:辅助 CM 治疗与停用生物制剂后 PV 复发率降低有关。
{"title":"Adjunctive Chinese medicine therapy reduces relapse of psoriasis vulgaris after discontinuation of biologics: a prospective registry-based cohort study.","authors":"Shan Huang, Xing-Wu Duan, Hua-Chao Zhang, Bo-Wen Dai, Yan-Ping Bai","doi":"10.1080/09546634.2024.2355261","DOIUrl":"https://doi.org/10.1080/09546634.2024.2355261","url":null,"abstract":"<p><strong>Background: </strong>Biologics have revolutionized psoriasis treatment; however, relapse of psoriasis after discontinuation of biologics remains unresolved.</p><p><strong>Objective: </strong>To assess the impact of adjunctive Chinese medicine (CM) therapy on relapse of psoriasis vulgaris (PV) after discontinuation of biologics.</p><p><strong>Methods: </strong>We constructed a prospective cohort study through a psoriasis case registry platform that enrolled patients treated with biologics (in combination with or without CM). The endpoint event was relapse, defined as loss of psoriasis area and severity index (PASI) 75.</p><p><strong>Results: </strong>A total of 391 patients completed the study and were included in the analysis, of whom 169 (43.2%) experienced relapse during follow-up. To minimize the bias, a 1:1 propensity score matching (PSM) was performed, generating matched cohorts of 156 individuals per group. Adjuvant CM therapy significantly associated with reduced incidence of relapse (HR =0.418, 95% CI = 0.289 ∼ 0.604, <i>p</i> < 0.001), and the protective effect of CM in the subgroup analysis was significant. In addition, PASI 90 response and disease duration were associated with relapse (<i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>Adjunctive CM therapy is associated with reduced relapse incidence in PV after discontinuation of biologics.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141066342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01Epub Date: 2024-05-26DOI: 10.1080/09546634.2024.2350227
Andreas Pinter, Kilian Eyerich, Antonio Costanzo, Alyssa Garrelts, Christopher Schuster, Can Mert, Anastasia Lampropoulou, Konstantinos Fotiou, Julia-Tatjana Maul, Kim A Papp
Purpose: Currently, in the treatment of moderate-to-severe psoriasis (PsO) there is a lack of evidence demonstrating optimal biologic treatment response with respect to disease duration. The aim of this post-hoc analysis, using real world data from the Psoriasis Study of Health Outcomes (PSoHO), is to provide evidence if early intervention with biologics is associated with better treatment outcomes and if there is any difference among drug classes or individual biologics.
Materials and methods: For this post-hoc analysis patients were categorised into two subgroups according to shorter (≤2 years) or longer (>2 years) disease duration. Analysis was performed on anti-interleukin (IL)-17A cohort vs other biologics cohort, anti-IL-17A vs other drug classes, and pairwise comparisons of ixekizumab vs individual biologics, provided that the statistical models converged. Analysis investigated the association of disease duration with the proportion of patients achieving 100% improvement in Psoriasis Area Severity Index score (PASI 100) at week 12. Adjusted comparative analyses, reported as odds ratio (OR), were performed using Frequentist Model Averaging (FMA) for each cohort or treatments within each subcategory of the subgroups.
Results: At week 12, anti-IL-17A and other biologics cohorts displayed minimal differences in numerical response rate for PASI 100 with respect to disease duration. The anti-IL-17A cohort showed a higher numerical PASI 100 response rate compared to the other biologic cohort irrespective of disease duration (≤2 years: 36.7% vs 21.8%; >2 years: 35.8% vs 21.9%).
Conclusion: Overall, the results do not clearly indicate that treating patients early is critical in achieving optimal patient outcomes. Furthermore, patients treated with ixekizumab show numerically higher response rates relative to other individual biologics irrespective of disease duration.
目的:目前,在中度至重度银屑病(PsO)的治疗中,缺乏证据表明生物制剂治疗对病程的最佳反应。这项事后分析的目的是利用银屑病健康结果研究(PSoHO)的真实数据,证明生物制剂的早期干预是否与更好的治疗效果相关,以及药物类别或单个生物制剂之间是否存在差异:在这项事后分析中,根据病程较短(≤2 年)或较长(>2 年)将患者分为两个亚组。在统计模型趋同的前提下,对抗白细胞介素(IL)-17A组与其他生物制剂组、抗IL-17A组与其他药物组以及ixekizumab与单个生物制剂的配对比较进行了分析。分析调查了疾病持续时间与第12周时银屑病面积严重程度指数(PASI 100)100%改善的患者比例之间的关系。使用频数模型平均法(FMA)对每个组群或亚组中每个亚类的治疗方法进行调整比较分析,以几率比(OR)报告:第 12 周时,抗-IL-17A 和其他生物制剂组在 PASI 100 数值反应率方面与病程的差异极小。抗IL-17A组与其他生物制剂组相比,无论病程长短,PASI 100数值应答率都更高(≤2年:36.7% vs 21.8%;>2年:35.8% vs 21.9%):总体而言,研究结果并没有明确表明早期治疗对患者获得最佳疗效至关重要。此外,无论病程长短,接受ixekizumab治疗的患者的反应率在数字上都高于接受其他生物制剂治疗的患者。
{"title":"Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO).","authors":"Andreas Pinter, Kilian Eyerich, Antonio Costanzo, Alyssa Garrelts, Christopher Schuster, Can Mert, Anastasia Lampropoulou, Konstantinos Fotiou, Julia-Tatjana Maul, Kim A Papp","doi":"10.1080/09546634.2024.2350227","DOIUrl":"https://doi.org/10.1080/09546634.2024.2350227","url":null,"abstract":"<p><strong>Purpose: </strong>Currently, in the treatment of moderate-to-severe psoriasis (PsO) there is a lack of evidence demonstrating optimal biologic treatment response with respect to disease duration. The aim of this post-hoc analysis, using real world data from the Psoriasis Study of Health Outcomes (PSoHO), is to provide evidence if early intervention with biologics is associated with better treatment outcomes and if there is any difference among drug classes or individual biologics.</p><p><strong>Materials and methods: </strong>For this post-hoc analysis patients were categorised into two subgroups according to shorter (≤2 years) or longer (>2 years) disease duration. Analysis was performed on anti-interleukin (IL)-17A cohort vs other biologics cohort, anti-IL-17A vs other drug classes, and pairwise comparisons of ixekizumab vs individual biologics, provided that the statistical models converged. Analysis investigated the association of disease duration with the proportion of patients achieving 100% improvement in Psoriasis Area Severity Index score (PASI 100) at week 12. Adjusted comparative analyses, reported as odds ratio (OR), were performed using Frequentist Model Averaging (FMA) for each cohort or treatments within each subcategory of the subgroups.</p><p><strong>Results: </strong>At week 12, anti-IL-17A and other biologics cohorts displayed minimal differences in numerical response rate for PASI 100 with respect to disease duration. The anti-IL-17A cohort showed a higher numerical PASI 100 response rate compared to the other biologic cohort irrespective of disease duration (≤2 years: 36.7% vs 21.8%; >2 years: 35.8% vs 21.9%).</p><p><strong>Conclusion: </strong>Overall, the results do not clearly indicate that treating patients early is critical in achieving optimal patient outcomes. Furthermore, patients treated with ixekizumab show numerically higher response rates relative to other individual biologics irrespective of disease duration.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141156038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01Epub Date: 2024-06-24DOI: 10.1080/09546634.2024.2366532
Tina Bhutani, Sayeli Jayade, Sanika Rege, Hannah Penton, Vardhaman Patel, Samaneh Kalirai, Daniel Wolin, Kimberly Boyle, Lauren Seigel
Purpose: This noninterventional, cross-sectional survey estimated the prevalence and consequences of residual disease in apremilast-treated US adults with moderate to severe psoriasis. Materials and Methods: Residual disease was defined as experiencing moderate, severe, or very severe psoriasis over the past week or having ≥3% body surface area affected, despite treatment. Factors associated with residual disease and its effects on flare-ups, humanistic burden, and health care resource utilization (HCRU) were evaluated. Results: Of the 344 apremilast users (mean age, 44.9 years; female, 65.4%), 174 (50.6%) had residual disease. It was more prevalent in Black versus White participants (OR, 4.5; 95% CI, 1.6-12.2), those receiving apremilast for ≥1 versus <1 year (OR, 16.5; 95% CI, 7.9-34.4), those reporting ≥2 versus 0 to 1 flare-ups during the past 3 months (OR, 10.0; 95% CI, 5.0-20.1), and those with ≥4 versus 1 to 3 body regions affected at time of survey (OR, 8.6; 95% CI, 3.8-19.8). Participants with versus without residual disease self-reported more psoriasis flare-ups over the past 3 months (mean, 4.7 vs 0.9; p < .001) and more anxiety (89.7% vs 50.0%; p < .001) and depression (69.0% vs 23.6%; p < .001) over the past 30 days. Conclusion: Generally, participants with versus without residual disease also had significantly more comorbidities and greater HCRU.
目的:这是一项非干预性横断面调查,目的是评估经阿普瑞司特治疗的美国中重度银屑病成人中残留疾病的患病率和后果。材料与方法:残留疾病的定义是:尽管接受了治疗,但在过去一周内出现中度、重度或极重度银屑病,或受影响的体表面积≥3%。评估与残留疾病相关的因素及其对复发、人文负担和医疗资源利用率(HCRU)的影响。研究结果在 344 名阿普瑞司特使用者(平均年龄 44.9 岁;女性 65.4%)中,174 人(50.6%)有残留疾病。黑人与白人相比(OR,4.5;95% CI,1.6-12.2),接受阿普瑞司特治疗≥1 次与 p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 结 论:一般来说,有残留疾病与无残留疾病的参与者之间存在着明显的差异:一般来说,有残留疾病的参与者与无残留疾病的参与者相比,合并症明显更多,HCRU 也更高。
{"title":"Evaluating prevalence and consequence of residual disease in individuals with psoriasis receiving apremilast treatment: results from a US patient survey.","authors":"Tina Bhutani, Sayeli Jayade, Sanika Rege, Hannah Penton, Vardhaman Patel, Samaneh Kalirai, Daniel Wolin, Kimberly Boyle, Lauren Seigel","doi":"10.1080/09546634.2024.2366532","DOIUrl":"https://doi.org/10.1080/09546634.2024.2366532","url":null,"abstract":"<p><p><b>Purpose:</b> This noninterventional, cross-sectional survey estimated the prevalence and consequences of residual disease in apremilast-treated US adults with moderate to severe psoriasis. <b>Materials and Methods:</b> Residual disease was defined as experiencing moderate, severe, or very severe psoriasis over the past week or having ≥3% body surface area affected, despite treatment. Factors associated with residual disease and its effects on flare-ups, humanistic burden, and health care resource utilization (HCRU) were evaluated. <b>Results:</b> Of the 344 apremilast users (mean age, 44.9 years; female, 65.4%), 174 (50.6%) had residual disease. It was more prevalent in Black versus White participants (OR, 4.5; 95% CI, 1.6-12.2), those receiving apremilast for ≥1 versus <1 year (OR, 16.5; 95% CI, 7.9-34.4), those reporting ≥2 versus 0 to 1 flare-ups during the past 3 months (OR, 10.0; 95% CI, 5.0-20.1), and those with ≥4 versus 1 to 3 body regions affected at time of survey (OR, 8.6; 95% CI, 3.8-19.8). Participants with versus without residual disease self-reported more psoriasis flare-ups over the past 3 months (mean, 4.7 vs 0.9; <i>p</i> < .001) and more anxiety (89.7% vs 50.0%; <i>p</i> < .001) and depression (69.0% vs 23.6%; <i>p</i> < .001) over the past 30 days. <b>Conclusion:</b> Generally, participants with versus without residual disease also had significantly more comorbidities and greater HCRU.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141447908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01Epub Date: 2024-01-11DOI: 10.1080/09546634.2023.2290360
Jarmila Čelakovská, Eva Čermáková, Ctirad Andrýs, Petra Boudkova, Jan Krejsek
{"title":"The differences in the count of B lymphocytes in atopic dermatitis patients with and without dupilumab therapy and in healthy subjects in pollen season and out of pollen season.","authors":"Jarmila Čelakovská, Eva Čermáková, Ctirad Andrýs, Petra Boudkova, Jan Krejsek","doi":"10.1080/09546634.2023.2290360","DOIUrl":"10.1080/09546634.2023.2290360","url":null,"abstract":"","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139428203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: To investigate the efficacy and safety of Cutegel® MAX (Cutegel) in the correction of moderate-to-severe nasolabial folds (NLFS) compared to Restylane® (Restylane, control).
Methods: This study was a 52-week, multicenter, randomized, double-blinded, active-controlled clinical trial. Qualified participants with moderate-to-severe NLFs were randomly assigned in a 1:1 ratio to receive Cutegel or Restylane. For the primary efficacy endpoint, the response rate was defined as the percentage of subjects exhibiting an improvement of at least one-point based on blinded evaluation of Wrinkle Severity Rating Scale (WSRS) at 24 weeks after injection. Other secondary efficacy endpoints and treatment-emergent adverse events (TEAEs) were assessed.
Results: Of 340 subjects randomized, 317 completed the week 52 visit. In the per protocol set (PPS), the blinded evaluator-assessed response rates at week 24 were 81.17% for Cutegel versus 77.56% for Restylane (p = 0.327). The between-group treatment differences in response rates were 3.60% [95% confidence interval (CI) = (-5.39%, 12.60%)], which demonstrated the noninferiority of Cutegel. Other secondary efficacy endpoints supported this. No significant differences were observed in the occurrence of adverse events between the two groups.
Conclusion: Similar to Restylane, Cutegel was effective and well tolerated in correcting moderate-to-severe NLFs among the Chinese population.
{"title":"A 52-week follow-up, multi-center, randomized, double-blinded comparison of efficacy and safety of two hyaluronic acid fillers for the treatment of moderate-to-severe nasolabial folds in Chinese population.","authors":"Hui Shao, Lu Wang, Jieying Tang, Lujia Chen, Shihong Zhang, Qiang Chen, Chuan Wang, Jianmin Yang, Weiwei Li, Hongyi Zhao","doi":"10.1080/09546634.2024.2378165","DOIUrl":"10.1080/09546634.2024.2378165","url":null,"abstract":"<p><strong>Introduction: </strong>To investigate the efficacy and safety of Cutegel<sup>®</sup> MAX (Cutegel) in the correction of moderate-to-severe nasolabial folds (NLFS) compared to Restylane<sup>®</sup> (Restylane, control).</p><p><strong>Methods: </strong>This study was a 52-week, multicenter, randomized, double-blinded, active-controlled clinical trial. Qualified participants with moderate-to-severe NLFs were randomly assigned in a 1:1 ratio to receive Cutegel or Restylane. For the primary efficacy endpoint, the response rate was defined as the percentage of subjects exhibiting an improvement of at least one-point based on blinded evaluation of Wrinkle Severity Rating Scale (WSRS) at 24 weeks after injection. Other secondary efficacy endpoints and treatment-emergent adverse events (TEAEs) were assessed.</p><p><strong>Results: </strong>Of 340 subjects randomized, 317 completed the week 52 visit. In the per protocol set (PPS), the blinded evaluator-assessed response rates at week 24 were 81.17% for Cutegel versus 77.56% for Restylane (<i>p</i> = 0.327). The between-group treatment differences in response rates were 3.60% [95% confidence interval (CI) = (-5.39%, 12.60%)], which demonstrated the noninferiority of Cutegel. Other secondary efficacy endpoints supported this. No significant differences were observed in the occurrence of adverse events between the two groups.</p><p><strong>Conclusion: </strong>Similar to Restylane, Cutegel was effective and well tolerated in correcting moderate-to-severe NLFs among the Chinese population.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141617805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}